人类二氧化碳无水酶II的双端抑制剂
Bidhan C Roy1, Abir L Banerjee, Michael Swanson
1Department of Chemistry, Biochemistry & Molecular Biology, North Dakota State University, Fargo, North Dakota 58105, USA.
Journal of the American Chemical Society
|October 14, 2004
概括
研究人员开发了一种新的"双端"策略,以提高酶抑制剂结合亲和力. 通过添加与表面残留物相互作用的接组,它们显著增强了对人类碳酸二酶II的抑制功效.
科学领域:
- 药用化学 医学化学
- 酶抑制剂设计 酶抑制剂设计
- 生物化学 生物化学
背景情况:
- 传统的酶抑制剂设计侧重于活性位点口袋,往往产生低于最佳的结合亲和力.
- 提高抑制剂亲和力对于开发有效疗法至关重要.
研究的目的:
- 引入一种用于增强酶抑制剂结合亲和力的新策略.
- 用"双端"方法将弱酶抑制剂转化为紧结合抑制剂.
主要方法:
- 设计具有结合组的抑制剂,以与表面暴露的氨基酸残留物相互作用.
- 测试人类碳酸无水酶II的抑制策略.
- 通过间隔组将一个弱抑制剂 (硫胺) 结合到 iminodiacetate-Cu2+.
主要成果:
- 这种"双端"方法显著提高了二硫胺胺对人类二氧化碳无水酶II的结合亲和力.
- 结合亲和力大约提高了两个数量级.
- 绑定的抑制剂与暴露在表面的西斯蒂丁残留物产生了强烈的相互作用.
结论:
- 开发的"双端"策略有效地提高了抑制剂结合亲和力.
- 这种方法提供了一种可通用的方法,用于将弱抑制剂转化为强效的抑制剂.
- 该战略对开发新型向酶治疗药物充满希望.
相关概念视频
Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


